Biotech

This comes at a time when US drugmakers are increasingly turning to China for new medicines

Its valuation is driven by a proprietary agentic AI platform and potential first-in-class cancer treatment

The company will support the transportation of biological and healthcare shipments

Huang’s immediate focus is to raise funding to support development of firm’s four assets

The biggest source of capital for biotech is no longer venture capital but family offices, he says

Demand for primate studies has grown amid an explosion of new biologics and next-generation therapies

China drugmakers are expanding globally through licencing deals with multinational giants

Private sector needs to translate AI productivity gains into cost savings for patients, experts say

Beijing has equally begun to protect its own nascent databases, passing a biosecurity law in 2020